Antenatal and newborn screening KPI data: Q1 summary factsheets (1 April to 30 June 2023)
Updated 14 March 2024
Applies to England
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/q1-1-april-to-30-june-2023-annb-and-ypa-screening-kpi-data/antenatal-and-newborn-screening-kpi-data-q1-summary-factsheets-1-april-to-30-june-2023
Please be aware that this data covers the time period through the COVID-19 pandemic. Provider performance should therefore be interpreted with caution.
In addition to this, some providers were justifiably not able to make timely data returns or validate their data in this period. We recommend looking at the historical trend data of services before the COVID-19 pandemic to help interpret the data.
This report should be read in conjunction with the full KPI data tables published each quarter.
1. Fetal anomaly screening
1.1 KPI FA2: coverage: fetal anomaly ultrasound
National performance of FA2 (see standard FASP-SO2) in Q4 2022 to 2023 was 98.8%, similar to the previous quarter. FA2 is collected 6 months (2 quarters) in arrears. The trend graph below shows that England FA2 performance has remained above the achievable threshold of 95% since 1 April 2019.
Out of all screening services who submitted data (138 out of 139) 138 met the acceptable threshold of 90%, with 135 meeting the achievable threshold of 95% and 21 of them reporting performance of 100%.
Activity for Q4 is presented by NHS regions. Coverage ranged from 98.3% in London to 99.1% in the North East and Yorkshire.
Quarter 4 performance
| Reporting period | Numerator | Denominator | Performance % | Completeness of data % |
|---|---|---|---|---|
| 1 January to 31 March 2023 | 139,255 | 140,992 | 98.8% | 99.3% |
| Region | Performance % |
|---|---|
| East of England | 98.9% |
| London | 98.3% |
| Midlands | 98.7% |
| North East and Yorkshire | 99.1% |
| North West | 99.1% |
| South East | 98.7% |
| South West | 98.7% |
| England | 98.8% |
1.2 KPI FA3
There is no intention to publish FA3 (see standard FASP-S01) by individual maternity service.
In Q1 139 out of 139 screening services submitted data.
1.3 KPI FA4: combined samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In Q1 2023 to 2024, national performance of FA4 for inadequate combined samples was 3.8%. FA4 is a KPI where a lower performance is better.
All 21 FASP laboratories submitted data, for a total of 138 maternity services.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 4,128 | 108,515 | 3.8% |
| Region | Performance % |
|---|---|
| East of England | 3.2% |
| London | 1.2% |
| Midlands | 4.8% |
| North East and Yorkshire | 5.0% |
| North West | 4.3% |
| South East | 5.9% |
| South West | 2.6% |
| England | 3.8% |
1.4 KPI FA4: quadruple samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In Q1 2023 to 2024, national performance of FA4 for inadequate quadruple samples was 8.1%. FA4 is a KPI where a lower performance is better.
All 21 FASP laboratories submitted data, for a total of 138 maternity services.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 1,099 | 13,554 | 8.1% |
| Region | Performance % |
|---|---|
| East of England | 5.4% |
| London | 3.3% |
| Midlands | 8.5% |
| North East and Yorkshire | 10.6% |
| North West | 5.4% |
| South East | 15.1% |
| South West | 15.4% |
| England | 8.1% |
2. Infectious diseases in pregnancy screening
2.1 KPI ID1: HIV coverage
National performance of ID1 (see standard IDPS-S01) in Q1 was 99.8%, remaining at a similar level to the previous quarter. The trend graph below shows that England ID1 performance has remained above the achievable threshold of 99% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 160,502 | 160,797 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.8% |
2.2 KPI ID2: diagnosis/intervention: timely assessment of women with hepatitis B
National performance of ID2 (see standard IDPS-S06) in Q1 was 74.7%. The trend graph below shows that England ID2 performance has remained above the acceptable threshold of 70% since 1 April 2020.
In Q1 2023 to 2024, responsibility for reporting ID2 shifted from individual maternity services to the Integrated Screening Outcomes Surveillance Service (ISOSS) who manage a centralised collection and reporting of data for the programme. The drop in performance from this quarter is a reflection on improved data quality and cohort identification and does not reflect any change of protocol or activity. For further information about ISOSS please visit https://www.ucl.ac.uk/integrated-screening-outcomes-surveillance/about-isoss.
ID2 is a small number KPI, therefore the data should be interpreted with caution.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 121 | 162 | 74.7% |
| Region | Performance % |
|---|---|
| East of England | 92.9% |
| London | 92.0% |
| Midlands | 60.0% |
| North East and Yorkshire | 57.9% |
| North West | 63.2% |
| South East | 68.8% |
| South West | 77.8% |
| England | 74.7% |
2.3 KPI ID3: coverage: hepatitis B
National performance of ID3 (see standard IDPS-S02) in Q1 was 99.8%, the same as the previous quarter. The trend graph below shows that England ID3 performance has remained above the achievable threshold of 99% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 160,500 | 160,792 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.8% |
2.4 KPI ID4: coverage: syphilis
National performance of ID4 (see standard IDPS-S03) in Q1 was 99.8%, the same as the previous quarter. The trend graph below shows that England ID4 performance has remained above the achievable threshold of 99% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 160,494 | 160,788 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.8% |
3. Sickle cell and thalassaemia screening
3.1 KPI ST1: coverage: antenatal screening
National performance of ST1 (see standard SCT-S01) in Q1 was 99.8%. The trend graph below shows that England ST1 performance has remained above the achievable threshold of 99% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 160,382 | 160,745 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.7% |
| North East and Yorkshire | 99.8% |
| North West | 99.7% |
| South East | 99.8% |
| South West | 99.6% |
| England | 99.8% |
3.2 KPI ST2: test: timeliness of antenatal screening
National performance of ST2 (see standard SCT-S02) in Q1 was 59.8%, higher than the previous quarter. The trend graph below shows that England ST2 performance dropped below the acceptable threshold of 50% for Q1 and Q2 of 2020 to 2021 but has been back above the acceptable threshold in every quarter since then.
Data suggests that while services were maintained, performance was affected for this KPI during COVID-19 in 2020. This is not unexpected as technical guidance in place at the time stated that services could offer screening later than 10 weeks.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 97,898 | 163,829 | 59.8% |
| Region | Performance % |
|---|---|
| East of England | 62.8% |
| London | 58.5% |
| Midlands | 51.9% |
| North East and Yorkshire | 71.1% |
| North West | 51.7% |
| South East | 62.2% |
| South West | 65.0% |
| England | 59.8% |
3.3 KPI ST3: test: completion of family origin questionnaire (FOQ)
National performance of ST3 (see standard SCT-S03) in Q1 was 98.1%, higher than the previous quarter. The trend graph below shows that England ST3 performance has remained above the acceptable threshold of 95% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 160,379 | 163,457 | 98.1% |
| Region | Performance % |
|---|---|
| East of England | 98.1% |
| London | 99.3% |
| Midlands | 96.9% |
| North East and Yorkshire | 98.1% |
| North West | 98.1% |
| South East | 97.7% |
| South West | 98.5% |
| England | 98.1% |
3.4 KPI ST4a: referral: timely offer of prenatal diagnosis (PND) to women at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4a (see standard SCT-S05) in Q1 was 46.4%, lower than the previous quarter. The trend graph below shows England ST4a performance since Q1 2020 to 2021. Thresholds have not yet been set for this KPI.
We have identified quality issues with the submitted data, therefore we recommend that regional performance is not compared. NHS England and NHS Improvement are reviewing this KPI with the aim of improving data quality.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 287 | 619 | 46.4% |
| Region | Performance % |
|---|---|
| East of England | 67.1% |
| London | 43.1% |
| Midlands | 35.0% |
| North East and Yorkshire | 58.5% |
| North West | 38.2% |
| South East | 50.8% |
| South West | 87.5% |
| England | 46.4% |
3.5 KPI ST4b: referral: timely offer of prenatal diagnosis (PND) to couples at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4b (see standard STC-S05) in Q1 was 66.4%, higher than the previous quarter. The trend graph below shows England ST4b performance since Q1 2020 to 2021. Thresholds have not yet been set for this KPI.
We have identified quality issues with the submitted data, therefore we recommend that regional performance is not compared. NHS England and NHS Improvement are reviewing this KPI with the aim of improving data quality.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 241 | 363 | 66.4% |
| Region | Performance % |
|---|---|
| East of England | 56.2% |
| London | 71.8% |
| Midlands | 52.9% |
| North East and Yorkshire | 78.8% |
| North West | 61.9% |
| South East | 63.6% |
| South West | 83.3% |
| England | 66.4% |
4. Newborn blood spot screening
4.1 KPI NB1: coverage of CCG responsibility at birth
National performance of NB1 (see standard NBS-S01a) in Q1 was 97.4%, higher than the previous quarter. The trend graph below shows that England NB1 performance has remained above the acceptable threshold of 95% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 131,077 | 134,570 | 97.4% |
| Region | Performance % |
|---|---|
| East of England | 99.7% |
| London | 96.3% |
| Midlands | 97.1% |
| North East and Yorkshire | 97.6% |
| North West | 96.9% |
| South East | 98.4% |
| South West | 96.4% |
| England | 97.4% |
4.2 KPI NB2: test: quality of the blood spot sample
National performance of NB2 (see standard NBS-S06) in Q1 was 2.9%, higher than the previous quarter. The trend graph below shows that England NB2 performance is above the acceptable threshold of 2%. NB2 is a KPI where a lower performance is better.
Due to COVID-19, during the Q1 (April to June 2020) time period newborn screening laboratories were instructed to relax blood spot acceptance criteria on samples that would normally have been rejected and to accept day 4 samples. Together these factors are likely to explain the reduced ‘avoidable repeat’ rate observed during Q1 2020 to 2021.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 4,103 | 142,101 | 2.9% |
| Region | Performance % |
|---|---|
| East of England | 1.7% |
| London | 2.2% |
| Midlands | 1.5% |
| North East and Yorkshire | 2.6% |
| North West | 2.8% |
| South East | 7.3% |
| South West | 2.0% |
| England | 2.9% |
4.3 KPI NB4: coverage of movers in
National performance of NB4 (see standard NBS-S01b) in Q1 was 79.3%, similar to the previous quarter. The trend graph below shows that England NB4 performance has remained below the acceptable threshold of 95% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 9,721 | 12,261 | 79.3% |
| Region | Performance % |
|---|---|
| East of England | 86.7% |
| London | 66.2% |
| Midlands | 78.4% |
| North East and Yorkshire | 87.8% |
| North West | 81.5% |
| South East | 84.5% |
| South West | 79.2% |
| England | 79.3% |
5. Newborn hearing screening
5.1 KPI NH1: coverage
National performance of NH1 (see standard NHSP-S01) in Q1 was 99.2%, higher than the previous quarter. The trend graph below shows that England NH1 performance has met the acceptable threshold of 98% since Q3 2020 to 2021.
During the COVID-19 pandemic in 2020 NHSP encouraged services to continue screening where safe to do so in line with national standards and the NHSP technical guidance. However, in some areas screening was delayed due to COVID-19 and we have seen lower coverage as a result. This particularly affected community services where Health Visitors suspended home visits.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 139,783 | 140,949 | 99.2% |
| Region | Performance % |
|---|---|
| East of England | 99.4% |
| London | 99.2% |
| Midlands | 99.3% |
| North East and Yorkshire | 99.2% |
| North West | 98.5% |
| South East | 99.5% |
| South West | 99.2% |
| England | 99.2% |
5.2 KPI NH2: diagnosis/intervention – time from screening outcome to attendance at an audiological assessment appointment
National performance of NH2 (see standard NHSP-S05) in Q1 was 92.3%, higher than the previous quarter. The trend graph below shows that England NH2 performance dropped significantly in Q1 2020 to 2021, however since then it has risen again.
During the COVID-19 pandemic in line with national guidance, many audiology departments closed. This resulted in a delay in the assessment of babies referred from the screen in most services.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 2,351 | 2,547 | 92.3% |
| Region | Performance % |
|---|---|
| East of England | 89.8% |
| London | 93.4% |
| Midlands | 93.5% |
| North East and Yorkshire | 90.6% |
| North West | 90.9% |
| South East | 91.8% |
| South West | 96.3% |
| England | 92.3% |
6. Newborn and infant physical examination screening
6.1 KPI NP1: coverage
National performance of NP1 (see standard NIPE-S01) in Q1 was 96.4%, similar to the previous quarter. The trend graph below shows that England NP1 performance has remained above the acceptable threshold of 95% since 1 April 2020.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 133,870 | 138,864 | 96.4% |
| Region | Performance % |
|---|---|
| East of England | 97.1% |
| London | 96.3% |
| Midlands | 96.6% |
| North East and Yorkshire | 96.2% |
| North West | 95.6% |
| South East | 96.3% |
| South West | 97.3% |
| England | 96.4% |
6.2 KPI NP3: diagnosis/intervention – timeliness of ultrasound scan of the hips for developmental dysplasia
NP3 (see standard NIPE-S03) was introduced in 2021 to 2022. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In Q1 2023 to 2024, national performance of NP3 was 74.3%.
Quarter 1 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| 1 April to 30 June 2023 | 9,979 | 13,423 | 74.3% |
| Region | Performance % |
|---|---|
| East of England | 81.1% |
| London | 73.3% |
| Midlands | 76.3% |
| North East and Yorkshire | 69.7% |
| North West | 62.8% |
| South East | 77.5% |
| South West | 80.4% |
| England | 74.3% |